Please ensure Javascript is enabled for purposes of website accessibility

Why Perrigo Stock Was Slipping Today

By Jeremy Bowman – Aug 11, 2021 at 4:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A disappointing earnings report pushed down shares of the over-the-counter medicine seller.

What happened

Shares of Perrigo (PRGO 1.32%) were sliding today after the consumer-facing healthcare company missed the mark in its second-quarter earnings report. 

As a result, the stock closed down 12.6% today.

A person holding a glass of water and a pill.

Image source: Getty Images.

So what

Perrigo, which sells unbranded over-the-counter medical products like acetaminophen as well as branded products like Prevacid, said that revenue in the second quarter was up 3.4% to $981.1 million, though that missed estimates at $1.02 billion. 

Organic sales increased 0.5%, which included a 2.3% decline in cold/cough remedies due to the impact of social distancing. 

On the bottom line, the company reported that adjusted earnings per share fell from $0.59 to $0.50 as it stepped up brand and marketing investments as the pandemic fades. That result missed expectations at $0.62, however. 

Perrigo sold its generic drug business for $1.55 billion earlier this year to focus entirely on the consumer market, and management is standing by that strategy despite disappointing results in the quarter. CEO Murray Kessler said, "Self-care has never been more important and with our portfolio reconfiguration completed and the investments made in technology, capabilities, talent, and manufacturing capacity, as a pure-play consumer company Perrigo is in a great position to capitalize on this trend."

Now what

Looking ahead, the company reaffirmed its net sales guidance, calling for 3% growth for the year, but it said it now expects full-year EPS to come in closer to the lower end of its guidance at $2.50-$2.70. That, along with the weak second-quarter results, explains why the stock declined by double-digits today.

Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Perrigo Stock Quote
$32.95 (1.32%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.